Oura, maker of the popular smart ring, launched its first proprietary artificial intelligence model built specifically for women’s health on February 24, 2026, and followed up on May 6, 2026, by rolling out two new features powered by that model: Hormonal Birth Control Support and Menopause Insights. The moves mark a shift for the company from general biometric tracking toward AI systems trained to interpret hormonal data across a woman’s entire reproductive lifespan.
Why Oura Built a Separate Model
Ricky Bloomfield, Oura’s chief medical officer, said the custom model represents “a fundamental shift in how we responsibly deploy AI in health to meet the needs of our members,” arguing that women’s health is too complex and too often overlooked to rely on generic, one-size-fits-all AI systems, according to a company announcement covered by TechCrunch and MobiHealthNews. Rather than adapting a general-purpose health chatbot, Oura says it trained the new model specifically on biometric data from its ring sensors combined with clinical research spanning the full reproductive spectrum, from early menstrual cycles through perimenopause and menopause.
What the New Features Actually Do
The Hormonal Birth Control Support feature is designed to help users on hormonal contraception understand how their method affects metrics the ring already tracks, such as temperature, heart rate variability, and sleep, which can otherwise look confusing or alarming without that context. Menopause Insights aims to help users recognize patterns associated with perimenopause and menopause, such as temperature fluctuations and sleep disruption, and connect those patterns to plain-language explanations grounded in clinical literature rather than generic wellness advice.
The Scale of the Problem Oura Says It’s Solving
Oura’s chief product officer, Holly Shelton, framed the launch around a large and long-underserved population, noting that “more than half of women in their reproductive years are using contraception and more than a billion women are moving through perimenopause and menopause,” yet have historically been asked “to rely on trial and error, vague reassurance, or generic symptom trackers.” That framing reflects a broader pattern in women’s health research, which has historically received less funding and clinical study than conditions predominantly affecting men, leaving many hormonal symptoms poorly explained by mainstream medicine.
Part of a Broader Femtech AI Wave
Oura is not alone in targeting this space. Apple added perimenopause and menopause support to its Health app’s cycle-tracking feature at WWDC 2026, NIH-backed startup Amissa launched an AI platform in January 2026 aimed at what it calls menopause care’s data blind spot, and Maven Clinic has introduced agentic AI across its women’s healthcare services covering fertility, pregnancy, and menopause. Fertility benefits company Carrot also expanded its AI metabolic health program to include menopause support in 2026. Market researchers tracking the sector have projected the AI-driven personalized nutrition and women’s health technology space to grow rapidly over the next decade as more companies compete for a historically underinvested market.
Questions About Data, Accuracy, and Overreach
Not everyone is convinced consumer wearables should be interpreting hormonal health at all. Critics, including some reproductive health researchers, have raised concerns that ring and wearable sensors were originally validated for general metrics like sleep and heart rate, not for diagnosing or characterizing hormonal transitions, and that AI-generated interpretations of ambiguous biometric patterns could cause unnecessary anxiety or, conversely, false reassurance if a genuine medical issue is misattributed to normal hormonal fluctuation. Privacy advocates have also flagged that reproductive health data is especially sensitive in the current U.S. legal landscape, where cycle and fertility data has in some cases been sought in legal proceedings following state abortion restrictions, making the security of these expanding datasets a significant concern for users.
What It Means and What’s Next
Oura’s expansion signals that wearable makers increasingly see hormonal health as a major growth category rather than a niche feature, and competitors are likely to accelerate their own AI-driven women’s health tools in response. The next test will be whether independent researchers can validate that Oura’s model-generated insights actually improve health outcomes or decision-making, rather than simply repackaging existing biometric data with more sophisticated language. Regulators have not yet weighed in specifically on AI-driven hormonal health interpretation tools sold as consumer wellness products rather than medical devices, a gap that could draw scrutiny as these features reach millions of users and touch on decisions, like contraception and menopause symptom management, that carry real health stakes.
